Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;36(11):1229-1238.
doi: 10.1007/s40263-022-00968-4.

Dextromethorphan/Bupropion: First Approval

Susan J Keam  1
Affiliations
Review

Dextromethorphan/Bupropion: First Approval

Susan J Keam. CNS Drugs. 2022 Nov.

Abstract

An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist] and the antidepressant bupropion hydrochloride (an aminoketone and CYP2D6 inhibitor that increases dextromethorphan bioavailability) [AUVELITYTM; dextromethorphan/bupropion], is being developed by Axsome Therapeutics, Inc. for the treatment of major depressive disorder (MDD), Alzheimer's disease agitation and smoking cessation. Dextromethorphan/bupropion was approved in the USA in August 2022 for the treatment of MDD in adults. This article summarizes the milestones in the development of dextromethorphan/bupropion leading to this first approval for the treatment of adults with MDD.

PubMed Disclaimer

References

    1. World Health Organisation. Depression fact sheet. 2021. https://www.who.int/news-room/fact-sheets/detail/depression . Accessed 13 Sep 2022.
    1. Davoudian PA, Wilkinson ST. Clinical overview of NMDA-R antagonists and clinical practice. Adv Pharmacol. 2020;89:103–29. - DOI - PubMed
    1. Henter ID, Park LT, Zarate CA Jr. Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs. 2021;35(5):527–43. - DOI - PubMed - PMC
    1. O'Gorman C, Jones A, Kennon K, et al. AXS-05 for neuropsychiatric disorders: scientific rationale and clinical development [abstract no. T16 plus poster]. In: ASCP 2018 Annual Meeting: Treatment of Psychiatric Illness Across the Lifespan. 2018.
    1. Fenton C, Lee A. Glutamatergic modulators are poorly understood, but promising therapies in depressive disorders. Drugs Therapy Perspect. 2022;38(1):7–12. - DOI

LinkOut - more resources